Most Read

The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment. Applicable to patients irrespective of cisplatin eligibility,

The regulatory decision represents the first new drug application (NDA) approval secured by the speciality pharmaceutical manufacturer. Cosette expects the therapy to be commercially accessible in the US

Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio’s TERA technology. The partnership divides research and clinical duties between

In the US, Ryzumvi is already marketed as the sole authorised treatment for pharmacologically-induced mydriasis. Under a global licensing agreement with Opus Genetics, Viatris holds exclusive rights to

The capital will fund clinical proof-of-concept testing for the biotechnology company’s lead gene therapy candidates, EST-101 and EST-201, whilst advancing its platform for direct kidney delivery. The total

It is a gamma-secretase modulator being developed as a potent once-daily oral therapy for the treatment and potential prevention of AD. According to the company, existing therapies approved

The initiative centres on creating a high-resolution, patient-derived molecular map of the fatal neurodegenerative disorder, which currently has few effective therapies. Under the terms of the agreement, Mayo

The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi. Under the first stage of the project, the companies will analyse clinical

Under the agreement, Alentis has secured an exclusive option to in-license linkers and payloads from PinotBio for use in its pipeline candidates. Financially, PinotBio will receive an upfront